Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X by Gerry Hanna, Curie Chair of Clinical Oncology at Trinity College Dublin, adding:
“And then there were EIGHT treatment schedules for LS-SCLC studied in randomized clinical trials.
- 45/30 (1.5 Gy QD)
- 60/40 (1.5 Gy BID)
- 54/30 (1.8 Gy BID)
- 60/30 (2 Gy QD)
- 66/33 (2 Gy QD)
- 70/35 (2 Gy QD)
- 42/15 (2.8 Gy QD)
- 45/15 (3 Gy QD)”
Quoting Gerry Hanna‘s post:
“Next up is a randomized phase 3 study of concurrent chemoRT in LS-SCLC.
530 patients randomized to 45Gy/5# vs 60Gy/30#.
No difference in survival outcomes.
Reduced pneumonitis and lymphoma rates.
New SOC?”
More posts featuring Drew Moghanaki on OncoDaily.
